Research Topics
Species | Donna WeberSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of boneRichard B Wilder
Department of Radiation Oncology, M D Anderson Cancer Center, Houston, Texas, USA
Cancer 94:1532-7. 2002..The authors analyzed multiple factors for myeloma-free survival (MFS) and cause-specific survival (CSS) in SPB patients treated with RT alone...- Newly diagnosed multiple myelomaDonna M Weber
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
Curr Treat Options Oncol 3:235-45. 2002..Its ease of administration along with stem cell preservation are likely to make this, followed by myeloablative therapy with stem cell support, the treatment of choice for untreated myeloma as confirmatory studies are completed... - Thalidomide alone or with dexamethasone for previously untreated multiple myelomaDonna Weber
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 21:16-9. 2003..To evaluate the activity of thalidomide in patients with asymptomatic multiple myeloma and of thalidomide-dexamethasone in patients with previously untreated symptomatic myeloma... - Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber
Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
N Engl J Med 357:2133-42. 2007..Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma... - Thalidomide and its derivatives: new promise for multiple myelomaDonna Weber
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Control 10:375-83. 2003..In addition, preliminary results of phase I studies of the immunomodulatory derivatives (IMiDs) of thalidomide have recently been reported... 
Symptom burden after autologous stem cell transplantation for multiple myelomaErica Campagnaro
Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 112:1617-24. 2008..Thorough assessment and understanding of symptoms and risk factors for symptom development after ASCT are logical first steps toward developing strategies aimed at reducing the symptom burden associated with this procedure...- Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian
The University of Texas M.D. Anderson Cancer Center, Box 429, 1515 Holcombe Blvd, Houston, TX 77030, USA
Semin Hematol 40:3-7. 2003..Our program of thalidomide/dexamethasone was a safe and effective combination for patients with resistant or relapsing disease, or as consolidation of partial remission after intensive therapy... - Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myelomaUday Popat
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 15:718-23. 2009..In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with chemotherapy and filgrastim is usually successful in these patients... - Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomesAnna V Christoforidou
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 13:543-9. 2007.... - Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myelomaAthanasios Anagnostopoulos
Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 100:2607-12. 2004..HDM should continue to be considered the standard preparative regimen for patients with myeloma... - Thalidomide and dexamethasone for resistant multiple myelomaAthanasios Anagnostopoulos
University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Br J Haematol 121:768-71. 2003..This experience supports the use of thalidomide-dexamethasone in myeloma patients with resistant disease and justifies further trials in newly diagnosed patients... - Risk factors for relapse after complete remission with high-dose therapy for multiple myelomaMuzaffar H Qazilbash
Department of Blood and Marrow Transplantation UT MD Anderson Cancer Center, Houston, TX 77030, USA
Leuk Lymphoma 47:1360-4. 2006..We conclude that high tumor mass at diagnosis predicts a significantly shorter remission duration for myeloma patients undergoing autografting... - High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myelomaMichele L Donato
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
Leuk Lymphoma 45:755-9. 2004..With a median follow up of 12.3 months, 89% of patients are alive. The TMC regimen is well tolerated and produces high response rates. Further evaluation of TMC to fully assess response and survival is ongoing... - 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trialsSergio Giralt
The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4006, USA
Blood 102:2684-91. 2003..With a minimum follow-up of 23 months, the median survival had not been reached and the median event-free survival was 22 months. 166Ho-DOTMP is a promising therapy for patients with multiple myeloma and merits further evaluation... - Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosisAlok C Bharti
Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Blood 103:3175-84. 2004..Overall, our results indicate that fresh cells from MM patients express constitutively active NF-kappaB and STAT3, and suppression of these transcription factors inhibits the survival of the cells... - International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)S Giralt
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Leukemia 23:1904-12. 2009..The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions... - Advances in treatment for relapses and refractory multiple myelomaTiffany Richards
MD Anderson Cancer Center, Houston, TX, USA
Med Oncol 27:S25-42. 2010.... - Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myelomaGaurav C Parikh
Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, TX 77030, USA
Biol Blood Marrow Transplant 15:812-6. 2009..In this analysis, a melphalan (Mel) dose of 200 mg/m(2) was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM)... - Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialMuzaffar H Qazilbash
Department of Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 14:1401-7. 2008..Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM... - Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureMichael Wang
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 112:4445-51. 2008..Studies were registered at http://www.clinicaltrials.gov under NCT00056160 and NCT00424047... - Novel agents for relapsed and/or refractory multiple myelomaSheeba K Thomas
Division of Cancer Medicine, Department of Lymphoma Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030 4009, USA
Cancer J 15:485-93. 2009..In this review, we will discuss the use of these novel agents and their combinations in patients with relapsed and/or refractory multiple myeloma... - Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplantMuzaffar H Qazilbash
Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 13:1066-72. 2007..02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma... - Thalidomide-dexamethasone as primary therapy for advanced multiple myelomaMichael Wang
University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
Am J Hematol 79:194-7. 2005..Thalidomide-dexamethasone was useful for these patients with advanced disease because of the high response rate and acceptable survival, with a low frequency of serious complications... 
Curability of multiple myelomaRaymond Alexanian
University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
Bone Marrow Res 2012:916479. 2012..In addition to immunofixation, more sensitive techniques for the detection of residual disease should be applied more consistently in patients with apparent complete remission in order to identify those with potential cure...- Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaDonna Weber
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
Semin Oncol 30:127-31. 2003.... - Lenalidomide in multiple myelomaSheeba K Thomas
The University of Texas M D Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
Best Pract Res Clin Haematol 20:717-35. 2007..We describe the role of lenalidomide in patients with symptomatic multiple myeloma that is newly diagnosed, relapsed and/or refractory to other therapies, or concurrent with primary amyloidosis... - Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantationMichele L Donato
Department of Blood and Bone Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA
Blood 107:463-6. 2006..High-dose melphalan followed by autologous transplantation appears effective for improving the symptoms and systemic manifestations of scleromyxedema... - Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research FoundationDonna M Weber
University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Oncology (Williston Park) 17:765-7. 2003..multiplemyeloma.org and will be published on a regular basis in ONCOLOGY... - Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myelomaMaha Ahmed
Department of Hematopathology, M.D. Anderson Cancer Center, The University of Texas, Houston, TX 77030-4095, USA
Eur J Haematol 71:174-8. 2003..Further studies are needed to establish the clinical relevance of this approach in comparison with other techniques... - 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemiaDonna M Weber
Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
Semin Oncol 30:243-7. 2003..These observations support the potential role of 2-CdA regimens as the treatment of choice for previously untreated WM... - Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progressionMeletios A Dimopoulos
Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
Leuk Lymphoma 45:2057-61. 2004..We conclude that rituximab is an effective treatment modality for patients with WM. Patients with both low levels of monoclonal protein and normal albumin are the best candidates for treatment with standard dose rituximab...